The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

CD228-directed Antibody-Anticalin® Bispecific Protein

Geo Regions

CD228-directed Antibody-Anticalin® Bispecific Protein

PF-08046049, SGN-BB228 is an investigational compound. Its safety and efficacy have not been established

Overview + Rationale

  • PF-08046049; SGN-BB228 is an investigational costimulatory bispecific molecule composed of a CD228-directed antibody and 4-1BB-directed Anticalin® proteins designed to provide a potent costimulatory bridge between tumor-reactive cytotoxic T cells and CD228-expressing tumor cells1 
  • PF-08046049; SGN-BB228 targets CD228 (melanotransferrin), which has minimal expression in normal tissue and is selectively expressed by multiple tumor types including melanoma, non-small cell lung cancer, colorectal cancer, pancreatic cancer, and mesothelioma1,2 
  • 4-1BB is an inducible costimulatory immune receptor expressed on activated T cells and other immune cell populations3,4

Mechanism of Action

Stage of Development

Small icon representing Melanoma
Advanced Melanoma
Phase 1 Monotherapy
Small icon Representing Advanced Solid Tumors
Advanced Solid Tumors
Phase 1 Monotherapy

Anticalin® is a registered US trademark of Pieris Pharmaceuticals Gmbh.

REFERENCES: 1. Updegraff B. SITC 2022. Poster 1201; 2. Sandall SL. Cancer Res. 2019;79: Abstract 2688; 3. Vinay DS. Mol Cancer Ther. 2012:1062-70; 4. Bartkowiak T. Front Oncol: 2015:117; 5. NCT05571839. https://clinicaltrials.gov/ct2/show/NCT05571839 Accessed February 25, 2024